相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Anirudh Prahallad et al.
NATURE (2012)
Survival in BRAF V600-Mutant Advanced Melanoma Treated with Vemurafenib
Jeffrey A. Sosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
Fei Su et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer
Qing Dong et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
Combinatorial Treatments That Overcome PDGFRβ-Driven Resistance of Melanoma Cells to V600EB-RAF Inhibition
Hubing Shi et al.
CANCER RESEARCH (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway
Mohammad Atefi et al.
PLOS ONE (2011)
Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032
Jonas N. Sondergaard et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2010)
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Gideon Bollag et al.
NATURE (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Mutations in GNA11 in Uveal Melanoma.
Catherine D. Van Raamsdonk et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner
Eric W. Joseph et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi
Catherine D. Van Raamsdonk et al.
NATURE (2009)
Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples
Laura E. MacConaill et al.
PLOS ONE (2009)
MEK1 mutations confer resistance to MEK and B-RAF inhibition
Caroline M. Emery et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway
Christine A. Pratilas et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis
Deliang Guo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Modeling genomic diversity and tumor dependency in malignant melanoma
William M. Lin et al.
CANCER RESEARCH (2008)
Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon
Kevin M. Haigis et al.
NATURE GENETICS (2008)
Melanoma biology and new targeted therapy
Vanessa Gray-Schopfer et al.
NATURE (2007)
BRAF mutation predicts sensitivity to MEK inhibition
DB Solit et al.
NATURE (2006)
Distinct sets of genetic alterations in melanoma
JA Curtin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS
W Zuidervaart et al.
BRITISH JOURNAL OF CANCER (2005)
Absence of mutations of the BRAF gene and constitutive activation of extracellular-regulated kinase in malignant melanomas of the uvea
A Weber et al.
LABORATORY INVESTIGATION (2003)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)